Back to top
more

Chemed (CHE)

(Real Time Quote from BATS)

$563.06 USD

563.06
41,486

+4.79 (0.86%)

Updated Nov 11, 2024 03:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Chemed's (CHE) Roto-Rooter Growth Aids, Macro Challenges Ail

by Zacks Equity Research

Chemed's (CHE) VITAS segment revenue decline during the second quarter gets somewhat offset by a geographically weighted average Medicare reimbursement rate increase of nearly 1.3%.

Here's Why You Should Hold on to Chemed (CHE) Stock Now

by Zacks Equity Research

Investors are optimistic about Chemed's (CHE) better-than-expected earnings and impressive Roto-Rooter results.

PNTG vs. CHE: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PNTG vs. CHE: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights H&R Block, Chemed, Suncor Energy, Open Text and Essent Group

by Zacks Equity Research

H&R Block, Chemed, Suncor Energy, Open Text and Essent Group are part of the Zacks top Analyst Blog.

Nalak Das headshot

5 Stocks in Focus That Recently Hiked Their Dividends

by Nalak Das

Investors should consider stocks that have recently raised their dividend payments. These are: HRB, CHE, SU, OTEX, ESNT.

Chemed (CHE) Q2 Earnings Surpass Estimates, Margins Grow

by Zacks Equity Research

Chemed (CHE) reports better-than-expected earnings in the second quarter, with a robust performance by the Roto-Rooter segment driving the top line.

Chemed (CHE) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 1.26% and 1.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Oak Street Health, Inc. (OSH) Surges 5.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Oak Street Health, Inc. (OSH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here's Why You Should Retain Chemed (CHE) Stock For Now

by Zacks Equity Research

Investors are optimistic about Chemed (CHE) owing to the robust demand for Roto-Rooter services and the ongoing rebound in senior housing admissions.

Chemed (CHE) Surges 3.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Chemed (CHE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's Why Investors Should Retain Chemed (CHE) Stock Now

by Zacks Equity Research

Strong performance across Chemed's (CHE) Roto-Rooter arm and increased home-based admissions raise investors' confidence.

Amedisys (AMED) Down 11% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Chemed's (CHE) Q1 Earnings Top Estimates, Margins Increase

by Zacks Equity Research

In Q1, Chemed's (CHE) VITAS revenue decline was primarily the result of a 4.1% decline in days of care.

Chemed (CHE) Q1 Earnings Surpass Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 6.68% and 1.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Hold on to Chemed (CHE) Stock For Now

by Zacks Equity Research

Investors are optimistic about robust performance by Chemed's (CHE) Roto-Rooter arm.

Here's Why You Should Retain Chemed (CHE) Stock For Now

by Zacks Equity Research

Investors are optimistic about Chemed's (CHE) better-than-expected earnings and robust performance by the Roto-Rooter arm.

Chemed (CHE) Roto-Rooter Sales Robust Despite COVID-19 Woes

by Zacks Equity Research

Chemed's (CHE) Roto-Rooter business gains from growing demand for plumbing, drain cleaning and excavation and water restoration services.

Chemed (CHE) Q4 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Chemed (CHE) reports better-than-expected earnings for the fourth quarter, with a robust performance by the Roto-Rooter arm driving the top line.

Chemed (CHE) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 3.75% and 0.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Chemed (CHE) Q4 Earnings Expected to Decline

by Zacks Equity Research

Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ADUS or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ADUS vs. CHE: Which Stock Is the Better Value Option?

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors are optimistic about Chemed (CHE), given impressive performance of the Roto-Rooter arm and solid growth in VITAS admissions.

Teleflex (TFX) Banks on Urolift Growth Amid Rising Expenses

by Zacks Equity Research

Despite reporting softer-than-expected revenues for the third quarter, Teleflex (TFX) notes that customer preference for UroLift continues to be driven by strong clinical results.

Henry Schein's (HSIC) New Deal Broadens Medical Supplies Arm

by Zacks Equity Research

The OMNIA Partners cooperative contract is expected to expand Henry Schein's (HSIC) offerings in the field of Point-of-Care testing, personal protective equipment and essential medical supplies.

Edwards (EW) States Long-Term Strategy, Provides 2022 View

by Zacks Equity Research

Edwards Lifesciences (EW) expects to reach significant milestones in 2022 including new product launches and progress in multiple significant clinical trials.